Louise leads We Venture Capital and holds board roles at several life sciences and genomics companies. She brings clinical experience as a medical doctor and clinical innovations fellow.
Gemma brings venture capital and board experience in diagnostics and health. She serves as a senior investment manager at We Venture and holds several board roles across the life sciences sector.
The financing will be used to expand technical teams and accelerate the commercialisation of its proteomics platform.
"Portal Biotech’s technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level on accessible desktop instruments that bring this state-of-the-art characterisation to any lab. These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing."
The round was led by We Venture Capital and Cross-Border Impact Ventures to support the development of liquid biopsy tests.
"The power of the OXcan proteomics biomarker discovery platform and the data generated by Oxcan stand out against the backdrop of other liquid biopsy companies, indicating a truly superior performance in the identification of early stage lung cancer"
The round was led by We Venture Capital and Cross-Border Impact Ventures to fund the global commercialisation of its liquid biopsy technology.
"Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy. Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes."
— Heinrich Roder, Senior Vice President of Research and Development
The funding extension was backed by new investor We Venture Capital alongside returning backers Nina Capital, Apex Ventures, and Cambridge Enterprise to prepare the firm for Series A.
"Zetta Genomics is already making a difference to patients as XetaBase empowers clinicians to make faster and more accurate diagnoses at scale. With this extension to our second seed funding round now finalised, we are scaling and innovating our technologies, and enhancing customer focus."
-20webclip.png)
